A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer

被引：1
|
作者：
Lynce, Filipa
Yeh, Eren D.
Regan, Meredith M.
Qin, Lei
Bay, Camden P.
Krop, Ian
Harrison, Beth T.
Nakhlis, Faina
Bellon, Jennifer
Overmoyer, Beth
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-12-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-12-18
引用
收藏
页数：3
相关论文
共 50 条
  • [31] The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better
    Al-Shamsi, Humaid O.
    Ibrahim, Nuhad K.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S694 - S696
  • [32] Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
    Montero, A. J.
    Diaz-Montero, C. M.
    Deutsch, Y. E.
    Hurley, J.
    Koniaris, L. G.
    Rumboldt, T.
    Yasir, S.
    Jorda, M.
    Garret-Mayer, E.
    Avisar, E.
    Slingerland, J.
    Silva, O.
    Welsh, C.
    Schuhwerk, K.
    Seo, P.
    Pegram, M. D.
    Glueck, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (01) : 215 - 223
  • [33] Efficacy of taxanes followed by anthracyclines as neoadjuvant therapy in HER2-negative breast cancer (BC): Analysis of everyday clinical practice.
    Rodriguez, Enrique Alanya
    Zamora, Catalina Falo
    Gil, Miguel J. Gil
    Anna, Petit
    Ortega, Raul
    Fernandez, Adela
    Morilla, Idoia
    Stradella, Agostina
    Cobo, Sara
    Simon, Sonia Pernas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Phase Ib study of rebastinib plus antitubulin therapy with paclitaxel (P) or eribulin (E) in patients with HER2-negative metastatic breast cancer (MBC)
    Anampa, J. D.
    Xue, X.
    Oh, S-y
    Kornblum, N.
    Sadan, S.
    Oktay, M. H.
    Condeelis, J.
    Sparano, J. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers
    Li, Bryan
    Yau, Thomas
    Leung, Roland
    Kwok, Gerry
    Tsang, Josephine
    Cheung, Polly
    Wong, T. T.
    Suen, Dacita
    Kwong, Ava
    Chiu, Joanne W.
    ADVANCES IN THERAPY, 2021, 38 (12) : 5752 - 5762
  • [36] Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers
    Bryan Li
    Thomas Yau
    Roland Leung
    Gerry Kwok
    Josephine Tsang
    Polly Cheung
    T. T. Wong
    Dacita Suen
    Ava Kwong
    Joanne W. Chiu
    Advances in Therapy, 2021, 38 : 5752 - 5762
  • [37] Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group
    Rastogi, P.
    Buyse, M.
    Swain, S.
    Jacobs, S.
    Robidoux, A.
    Liepman, M.
    Dy, P.
    Geyer, C., Jr.
    Wolmark, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
    Ni, M.
    Zhou, L.
    Lu, Y.
    Zhang, L.
    Li, X.
    Chen, M.
    Yang, A.
    Zhang, L.
    Xu, F.
    Yuan, Z.
    Wang, S.
    Shi, Y.
    An, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1490 - S1490
  • [39] NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).
    Tan, Antoinette R.
    Buyse, Marc E.
    Rastogi, Priya
    Jacobs, Samuel A.
    Robidoux, Andre
    Flynn, Patrick J.
    Thirlwell, Michael P.
    Fehrenbacher, Louis
    Stella, Philip J.
    Goel, Rakesh
    Julian, Thomas B.
    Provencher, Louise
    Bury, Martin Joseph
    Paik, Soonmyung
    Geyer, Charles E.
    Swain, Sandra M.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] The Efficacy of Eribulin Monotherapy after Anthracycline and Taxane in HER2-Negative Metastatic Breast Cancer
    Tsushita, Natsuko
    Shimoi, Tatsunori
    Kitano, Atsuko
    Shimomura, Akihiko
    Kodaira, Makoto
    Yunokawa, Mayu
    Yonemori, Kan
    Shimizu, Chikako
    Fujiwara, Yasuhiro
    Tamura, Kenji
    ANNALS OF ONCOLOGY, 2016, 27
12345